Abstract
Background/Objectives: We aimed to describe clinical burden, treatment patterns, and reported adherence in children with presumed HbSS in Southeastern Türkiye. Methods: This retrospective single-center study included 41 children with sufficient clinical records covering 2011–2021; the retrospective chart review was conducted in 2025, and clinical events after 2021 were not included. Diagnosis was supported by hemoglobin electrophoresis at presentation to our center and parental electrophoresis results. Complete molecular records were unavailable. Annual pain-crisis frequency was the average of hospital-documented events over follow-up. Results: There were 24 girls and 17 boys; mean age at last assessment was 9.49 ± 4.55 years. Fifteen children (36.6%) averaged ≥3 pain crises/year. Hydroxyurea had been prescribed to 38 children: 34 reported regular use and four adolescents reported irregular use at the last assessment. Three two-year-old children had not started treatment. The ≥3-crises/year category included 8/34 regular users, 4/4 irregular users, and 3/3 untreated children. An exploratory comparison among prescribed patients yielded a two-sided Fisher exact p-value of 0.0067. No hematologic toxicity requiring dose reduction or treatment discontinuation was documented. Eight children received chronic transfusions and deferasirox. Acute chest syndrome and ischemic stroke were documented in three and two children, respectively. Conclusions: This series distinguishes treatment prescription, reported regular use, and age-related non-initiation within a population with ongoing morbidity. The different timeframes for adherence and crisis assessment and the small subgroups preclude causal interpretation of treatment effects.